By Olivia Bugault


Swiss life-sciences company Lonza Group AG has signed an agreement for the potential sale of two sites to NextPharma, one in Ploermel, France, and another in Edinburgh, Scotland, the two companies said jointly on Tuesday.

The two sites, which are specialized in lipid oral dosage forms and employ a total of 390 workers, will allow the contract development and manufacturing organization NextPharma to develop its technology offering in this field, the companies said.

"With this intended divestment, Lonza plans to exit both softgels and liquid-filled hard capsules for the pharma market, aside from retaining capability for feasibility studies as part of a technology selection offering," they said.

The agreement is subject to regulatory approvals, the companies said.


Write to Olivia Bugault at


(END) Dow Jones Newswires

January 19, 2021 01:51 ET (06:51 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.